Research & Development
Publications
Data from Pivotal Trials of Etripamil in PSVT
Etripamil Nasal Spray for Conversion of Repeated Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia During Long‐Term Follow‐Up: Results From the NODE‐302 Study
Journal of the American Heart Association
Self-administered Intranasal Etripamil Using a Symptom-prompted, Repeat-dose Regimen for Atrioventricular-nodal-dependent Supraventricular Tachycardia (RAPID): A Multicentre, Randomised Trial
The Lancet
Impact of Investigational, at-Home, Self-administered, Intranasal Etripamil on the Need for Additional Medical Intervention in Patients with Supraventricular Tachycardia
ISPOR
Self-administered Etripamilfor Termination of Spontaneous Paroxysmal Supraventricular Tachycardia: Primary Analysis fromthe RAPID Study
American Heart Association
First Randomized, Multicenter, Placebo-Controlled Study of Self-Administered Intranasal Etripamil for Acute Conversion of Spontaneous Paroxysmal Supraventricular Tachycardia (NODE-301)
American Heart Association
Rationale For and Design ofa Multicenter, Placebo-controlled, Phase 3 Study to Assess Efficacy and Safety of Intranasal Etripamilforthe Conversion of Paroxysmal Supraventricular Tachycardia
American Heart Journal
HRS 22: Long-Term Outcomes of the NODE-302 Study | Dr James Ip
Heart Rhythm Society
Analysis of Clinical Outcomes in the NODE-301 Trial
American College of Cardiology
Additional Clinical Data of Etripamil in PSVT
Potential New Therapeutic Option for the Treatment of SVT in Acute and Chronic Settings
EHRA
Very Low Efficacy of Vagal Maneuvers in Terminating Paroxysmal Supraventricular Tachycardia: Results From the NODE-301 Study
Heart Rhythm Society
Etripamil Nasal Spray Reduces Heart Rate in Patients with Paroxysmal Supraventricular Tachycardia Prior to Conversion to Sinus Rhythm
American Heart Association
Etripamil Nasal Spray for Acute Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia
Heart Rhythm Society
Etripamil Nasal Spray for Rapid Conversion of Supraventricular Tachycardia to Sinus Rhythm. Journal of the American College of Cardiology. 2018.
Journal of the American College of Cardiology
Clinical Data of Etripamil in Atrial-Fibrillation with Rapid Ventricular Response (AF-RVR)
A Multicenter, Phase 2, Randomized, Controlled Study of the Efficacy and Safety of Etripamil Nasal Spray for the Acute Reduction of Rapid Ventricular Rate in Patients with Symptomatic Atrial Fibrillation (ReVeRA-201)
Circulation: Arrhythmia and Electrophysiology
Efficacy and Safety of Etripamil Nasal Spray for the Acute Reduction of Rapid Ventricular Rate in Patients with Atrial Fibrillation: Phase 2 ReVeRa-201
American Heart Association
Effect of Etripamil Nasal Spray on Ventricular Rate in Patients Experiencing Symptomatic Atrial Fibrillation: Presentation
Heart Rhythm Society
Effect of Etripamil Nasal Spray on Ventricular Rate in Patients Experiencing Symptomatic Atrial Fibrillation: Poster
Heart Rhythm Society
PSVT Disease Burden
Prevalence and Incidence of Patients with Paroxysmal Supraventricular Tachycardia inthe United States.
Journal of Cardiovascular Electrophysiology
Trends in Healthcare Resource Use and Expenditures in Patients with Newly Diagnosed Paroxysmal Supraventricular Tachycardia in the United States. 2021.
American Heart Journal
Disparities in the Management of Newly Diagnosed Paroxysmal Supraventricular Tachycardia for Women Versus Men in the United States. Journal of the American Heart Association. 2020.
Journal of the American Heart Association
Healthcare Resource Use and Expenditures in Patients Newly Diagnosed with Paroxysmal Supraventricular Tachycardia. American Journal of Cardiology. 2020.
American Journal of Cardiology